BidaskClub downgraded shares of Horizon Pharma (NASDAQ:HZNP) from a buy rating to a hold rating in a report published on Tuesday morning.
A number of other equities research analysts have also recently commented on the company. Jefferies Group increased their target price on Horizon Pharma from $16.00 to $21.00 and gave the company a buy rating in a report on Tuesday, November 7th. Stifel Nicolaus reiterated a buy rating and set a $20.00 target price on shares of Horizon Pharma in a report on Sunday, October 22nd. Mizuho upgraded Horizon Pharma from a neutral rating to a buy rating and increased their target price for the company from $12.00 to $18.00 in a report on Friday, January 12th. ValuEngine upgraded Horizon Pharma from a hold rating to a buy rating in a report on Monday, October 16th. Finally, Cantor Fitzgerald set a $17.00 target price on Horizon Pharma and gave the company a buy rating in a report on Friday, December 1st. One research analyst has rated the stock with a sell rating, three have given a hold rating and eleven have issued a buy rating to the company’s stock. Horizon Pharma has a consensus rating of Buy and an average target price of $19.25.
Horizon Pharma (NASDAQ HZNP) traded down $0.17 on Tuesday, hitting $15.04. The company had a trading volume of 1,261,899 shares, compared to its average volume of 1,800,000. The firm has a market cap of $2,500.00, a PE ratio of -4.95, a P/E/G ratio of 0.70 and a beta of 1.30. The company has a current ratio of 1.64, a quick ratio of 1.52 and a debt-to-equity ratio of 1.89. Horizon Pharma has a 1-year low of $9.45 and a 1-year high of $17.69.
Horizon Pharma (NASDAQ:HZNP) last released its quarterly earnings results on Monday, November 6th. The biopharmaceutical company reported $0.26 earnings per share for the quarter, topping analysts’ consensus estimates of $0.22 by $0.04. The business had revenue of $271.60 million for the quarter, compared to analysts’ expectations of $259.74 million. Horizon Pharma had a positive return on equity of 20.22% and a negative net margin of 45.28%. The company’s revenue was up 30.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.70 EPS. equities analysts expect that Horizon Pharma will post 0.72 earnings per share for the current fiscal year.
Institutional investors have recently modified their holdings of the business. Advantage Investment Management LLC lifted its stake in shares of Horizon Pharma by 164.8% during the 3rd quarter. Advantage Investment Management LLC now owns 7,874 shares of the biopharmaceutical company’s stock worth $100,000 after purchasing an additional 4,900 shares during the period. Family Management Corp purchased a new position in shares of Horizon Pharma during the 2nd quarter worth $131,000. Brown Advisory Inc. purchased a new position in shares of Horizon Pharma during the 3rd quarter worth $145,000. Prudential Financial Inc. lifted its stake in shares of Horizon Pharma by 5.0% during the 2nd quarter. Prudential Financial Inc. now owns 17,510 shares of the biopharmaceutical company’s stock worth $208,000 after purchasing an additional 830 shares during the period. Finally, Fox Run Management L.L.C. lifted its stake in shares of Horizon Pharma by 21.5% during the 4th quarter. Fox Run Management L.L.C. now owns 19,200 shares of the biopharmaceutical company’s stock worth $280,000 after purchasing an additional 3,400 shares during the period. 86.58% of the stock is currently owned by institutional investors.
WARNING: This piece was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece on another publication, it was stolen and republished in violation of US and international copyright law. The correct version of this piece can be read at https://www.dispatchtribunal.com/2018/01/19/horizon-pharma-hznp-cut-to-hold-at-bidaskclub.html.
Horizon Pharma Company Profile
Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.
Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.